Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25692395 | 0.81 | CDC7 (0.61) | ULK1PTK2MAPK9MAPK10LRRK2 | |
| SCHEMBL2029526 | 0.81 | PTK2 (0.58) | ULK1PTK2MAPK9MAPK10CDC7 | |
| SCHEMBL21258417 | 0.81 | CDC7 (0.58) | ULK1PTK2MAPK9MAPK10LRRK2 | |
| SCHEMBL30692349 | 0.80 | MAPK10 (0.64) | PTK2MAPK9MAPK10 | |
| SCHEMBL1231671 | 0.80 | MAPK10 (0.64) | PTK2MAPK9MAPK10 | |
| SCHEMBL17544940 | 0.79 | ULK1 (0.76) | ULK1PTK2MAPK9MAPK10LRRK2 | |
| SCHEMBL5566681 | 0.79 | LRRK2 (0.56) | ULK1PTK2LRRK2CDK9MAPK3 | |
| SCHEMBL1627996 | 0.79 | PTK2 (0.70) | PTK2JAK2NTRK1TYK2KDR | |
| SCHEMBL25692495 | 0.78 | PTK2 (0.68) | PTK2CDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL2594649 | 0.78 | ULK1 (0.67) | ULK1PTK2MAPK9MAPK10LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438056-B1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | ULK1 965/4885PTK2 2/4885MAPK9 548/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | ULK1 965/4885PTK2 2/4885MAPK9 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.